Cipla reports Rs 28,163 crore revenue for FY26 with robust growth in India and Africa

Yash Agarwal — Wed, 13 May 2026 07:29:09 +0000

Cipla Limited announced its audited consolidated financial results for the quarter ended 31st March 2026, reporting a significant annual revenue of ₹28,163 crore for FY26. The company achieved double-digit growth in its One India business, which grew by 15% year-on-year, driven by strong performances across its Branded Prescription, Trade Generics, and Consumer Health segments.

In the North American market, Cipla recorded quarterly revenue of $155 million, supported by demand in its differentiated portfolio and a steady base business. The company also secured regulatory approval for its first AB-rated gVentolin, marking a significant milestone for its U.S. operations.

Cipla’s One Africa business continued its strong momentum, achieving a 14% year-on-year growth in USD terms for the quarter. The Emerging Markets and Europe segment also delivered $90 million in revenue, demonstrating resilience amid geopolitical uncertainties.

The company’s R&D investments stood at ₹509 crore, accounting for 7.8% of sales for the quarter, underscoring its commitment to product development and innovation.

Cipla’s net cash position was reported at ₹10,526 crore, with debt primarily comprising lease liabilities and working capital requirements. The company declared a final dividend of ₹13 per equity share for the financial year ended 31st March 2026, subject to shareholder approval at the upcoming annual general meeting.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

One Africa | Business Upturn

Cipla reports Rs 28,163 crore revenue for FY26 with robust growth in India and Africa